Leading Life Sciences CEOs to Honor Genzyme CEO Henri Termeer with Lifetime Achievement Award at 5th Annual Boston Biotech

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- The Boston Biotech CEO Conference today announced that it will present Genzyme chairman, president and chief executive officer Henri A. Termeer with the conference series’ Lifetime Achievement Award on Monday, June 14 in Cambridge, Mass. Mr. Termeer, who was selected via vote of his peers, will be recognized for exemplifying leadership, innovation and integrity as a biotech chief executive.

“Henri is a pioneer in the biotech community and has built one of the most successful biotechnology companies in the industry. His creativity, vision and passion has been an inspiration not only to his peers in biotech, but also to those in larger pharmaceutical companies who appreciate his willingness to brave new markets and pursue unchartered territory in drug development,” said chief executive officer of GlaxoSmithKline and Boston Biotech CEO Conference keynote speaker Andrew Witty.

Mr. Termeer is recognized globally as a pioneer in developing and delivering treatments to patients with rare genetic disorders. He was appointed president of Genzyme Corporation in 1983, chief executive officer in 1985 and chairman in 1988. In that time, Genzyme has grown to be one of the world’s leading biotechnology companies. Apart from his work at Genzyme, Mr. Termeer is widely acknowledged for his contributions to the industry, humanitarian assistance, advocating policy issues and providing access to health care.

“The idea for the award originated from the conference’s key purpose: to bring together chief executives to share insights, challenges and opportunities that can improve our industry,” said Richard Pops, chairman, president and chief executive officer of Alkermes and co-host of the Boston Biotech CEO Conference.

“Henri has been a mentor to many of us in Boston and beyond, and he clearly personifies the qualities that we celebrate in our colleagues each year at this conference,” added Christoph Westphal, a co-organizer of the meeting. “We are proud to honor his distinguished career and the value he will no doubt continue to bring to Genzyme and our industry.”

The CEO Lifetime Achievement Award will be presented to Mr. Termeer during the conference’s opening program on the evening of Monday, June14 at the Charles Hotel in Cambridge, Mass. The conference program on Monday and Tuesday, June 14-15 will feature keynote and panel presentations by notable political and business luminaries who play key roles in the life sciences industry:

  • Charlie Baker, Massachusetts gubernatorial candidate
  • Jeff Kindler, chairman and chief executive officer, Pfizer
  • Deval Patrick, Governor of Massachusetts
  • Josh Sharfstein, principal deputy commissioner, Food & Drug Administration
  • Andrew Witty, chief executive officer, GlaxoSmithKline

More than 160 life sciences chief executives are expected to be in attendance over the two-day conference, including Julian Adams, Infinity Pharmaceuticals; Rich Aldrich, Longwood Founders Fund; Tim Barberich, founder of Sepracor; Josh Boger, founder of Vertex Pharmaceuticals; Mike Bonney, Cubist Pharmaceuticals; Deborah Dunsire, Millennium: The Takeda Oncology Company; Matthew Emmens, Vertex Pharmaceuticals; Tuan Ha-Ngoc, AVEO Pharmaceuticals; John Maraganore, Alnylam Pharmaceuticals; Jim Mullen, Biogen Idec; Adelene Perkins, Infinity Pharmaceuticals; Richard Pops, Alkermes; Henri Termeer, Genzyme and Christoph Westphal.

ABOUT THE BOSTON BIOTECH CEO CONFERENCE

The Boston Biotech CEO Conference is a unique and intimate forum that encourages discussions among some of the most influential chief executives in the life sciences industry. This invitation-only event features individual presentations, as well as panel discussions by internationally recognized economic and health care policy experts. The conference is sponsored by Alexandria Real Estate Equities, Cooley LLP, Ledbetter Stevens, L.E.K. Consulting, Longwood Founders Fund, Massachusetts Biotechnology Council, Morgan Stanley, Pure Communications, Inc., and Xconomy. For more information or to register, visit www.bbbiotechconference.com.



CONTACT:

Pure Communications
Ashlea Kosikowski, 910-547-7093, [email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.